“I am satisfied with the progress made by AppYea / SleepX this year. As part of the long-term goal, AppYea Inc. (OTCPINK: APYP) has taken the first step to advance the prospects of the company. As noted in our quarterly report yesterday to the OTC for the last fiscal quarter, the share split, for which we are awaiting FINRA approval, is a proactive move that we believe will position us better to succeed and generate ultimately value for all of the company’s shareholders. The ultimate goal is to increase the visibility of our action within the investment community by improving long-term liquidity and creating an attractive business environment for institutional investors in the hope of expanding our shareholder base. confident in the anticipated commercialization prospects of the SleepX DreamIT X3. in 2022 “.
Mr. Molchadsky continued, “In conjunction with the corporate actions, AppYea has secured sources of funding which we believe will help the Company to restructure highly dilutive past debt and provide the necessary capital to enable the Company to move forward on several fronts, including:
1. Completion of the merger between AppYea and SleepX – we are awaiting the necessary regulatory approvals.
2. Completion of development and start of manufacturing of the first product for the treatment of snoring.
SleepX intends to start a pilot in December with a leading computer hardware maker after it withstood the company’s endurance tests.
3. Preparation for the start of clinical trials of the product for the treatment of Sleep Apnea.
4. Locate and acquire synergistic technologies and expand the variety of products in the field of sleep and breathing.
Looking ahead, the Company’s primary objective is to ensure the long-term success of the Company by acting in the best interests of all of our shareholders.
Thank you for your continued support and your patience ”.[Legal Notice Regarding Forward-Looking Statements]
This press release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those stated in this document. No statement herein should be construed as an offer or the solicitation of an offer to buy or sell any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions on which they are based are reasonable, it cannot guarantee that these expectations and assumptions will prove to be correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words “may”, “will”, “should”, “could”, “expect”, ” anticipate, “” estimate “,” believe “,” intend “or” project “or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to place undue reliance on these forward-looking statements, as such statements are subject to many factors and uncertainties, including, but not limited to, adverse economic conditions, intense competition, entry of new competitors and products, and local government regulations, inadequate capital, unforeseen costs and operating deficits, increased general and administrative expenses, unforeseen losses, financial condition and stock prices, inability to carry out research, development and marketing and other specific risks. APYP assumes no obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934, as amended.
Copyright © acrofan All rights reserved